“In March we received a list of questions from the EMA, which we answered and submitted immediately. At the time, we expected approval in April 2022. However, the EMA only responded eight weeks later and presented another list of questions that we also answered. As a result, the approval was postponed by two months to June 2022, “said CEO Thomas Lingelbach in an exclusive interview with “Business Insider”. The same application for approval was also sent to the British approval authority – which had already approved it.
Valneva announced on Friday that the EU was reducing order quantities – but so much that “the sustainability of Valneva’s COVID-19 vaccine program” could not be guaranteed. Information from “Business Insider”, according to which the twelve million cans planned for Germany alone will be reduced to one million, confirms Lingelbach indirectly: “Of course I can’t say anything about the details, but the magnitude is there.”
Lingelbach is convinced that the vaccination rate can be increased with his company’s inactivated vaccine: “A market study we carried out shows that we could increase the vaccination rate by one to two percent with our vaccination. Our conventional vaccine would also pick people up who are skeptical about an mRNA vaccination. I think it would be wrong not to get this option.”
The manager added that he was expecting another corona wave in autumn and winter: “I think that we can expect another significant corona wave. We can see that from the speed at which the variants are developing – in my opinion, another outbreak is not possible impede.”
DJG/hru
FRANKFURT (Dow Jones)
Leverage must be between 2 and 20
No data
More news about Valneva
Image sources: mundissima / Shutterstock.com